NASDAQ:ADVM - Adverum Biotechnologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.20 +0.05 (+0.97 %)
(As of 07/17/2018 01:28 AM ET)
Previous Close$5.15
Today's Range$4.80 - $5.30
52-Week Range$2.40 - $8.59
Volume765,400 shs
Average Volume1.09 million shs
Market Capitalization$320.70 million
P/E Ratio-4.03
Dividend YieldN/A
Adverum Biotechnologies logoAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio26.88
Quick Ratio26.88


Trailing P/E Ratio-4.03
Forward P/E Ratio-4.16
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.85 million
Price / Sales175.03
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.27


EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,571.30%
Return on Equity-28.51%
Return on Assets-26.45%


Outstanding Shares62,270,000
Market Cap$320.70

The Truth About Cryptocurrencies

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) released its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The biotechnology company earned $0.22 million during the quarter, compared to analyst estimates of $0.40 million. Adverum Biotechnologies had a negative net margin of 3,571.30% and a negative return on equity of 28.51%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

3 Wall Street analysts have issued twelve-month target prices for Adverum Biotechnologies' stock. Their predictions range from $3.50 to $12.00. On average, they anticipate Adverum Biotechnologies' share price to reach $7.1667 in the next twelve months. This suggests a possible upside of 37.8% from the stock's current price. View Analyst Ratings for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (7/10/2018)
  • 2. Chardan Capital analysts commented, "We note PRVs have in 2017 sold for: 1) $130 mm to Ultragenyx Pharmaceutical (unrated), announced 18 December 2017; 2) $125 mm to BioMarin Pharmaceutical (unrated), announced 27 November 2017, and 3) $125 mm to Sarepta Therapeutics (unrated), announced 21 February 2017. We understand Spark will announce the pricing of Luxturna in January, and that the drug will be available in late 1Q18. The Midwest CEPAC will convene to discuss the Institute for Clinical and Economic Review (ICER) document on Luxturna, on 25 January 2018. Luxturna’s approval is an important (+) for GT, particularly for AAV-based ophthalmology companies. We understand Luxturna is the first gene therapy approved in the US for a genetic disease, the first in vivo and AAV-based gene therapy approved in the US, and the first pharmacologic treatment approved for an inherited retinal disease (IRD)." (12/19/2017)

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 4,675,907 shares, an increase of 122.9% from the June 15th total of 2,097,578 shares. Based on an average daily volume of 1,282,932 shares, the days-to-cover ratio is presently 3.6 days. Currently, 9.6% of the shares of the company are sold short. View Adverum Biotechnologies' Current Options Chain.

Who are some of Adverum Biotechnologies' key competitors?

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 59)
  • Dr. Mehdi Gasmi, Chief Science & Technology Officer (Age 51)
  • Dr. Amber Salzman, Consultant (Age 56)
  • Ms. Leone D. Patterson, Interim Pres, CEO, Sr. VP & CFO (Age 55)
  • Dr. Jennifer Cheng, VP, Gen. Counsel & Corp. Sec. (Age 45)

Has Adverum Biotechnologies been receiving favorable news coverage?

Media stories about ADVM stock have been trending somewhat negative this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a media sentiment score of -0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.35 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $5.20.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $320.70 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]

MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.